Home
MDGL
MDGL News

Latest Madrigal Pharmaceuticals Inc. (MDGL) News on July 1, 2025

Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra

Insider Monkey

7 days ago

Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra

Madrigal poised to enter European MASH market after CHMP endorsement

Pharmaceutical Technology

11 days ago

Madrigal poised to enter European MASH market after CHMP endorsement

MT Newswires

11 days ago

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires

11 days ago

Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount

MT Newswires

11 days ago

Madrigal Gets Positive Opinion From EMA for Resmetirom to Treat Liver Disease

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

GlobeNewswire

11 days ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

14 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Exploring High Growth Tech Stocks In The US Market

Simply Wall St.

19 days ago

Exploring High Growth Tech Stocks In The US Market

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

GlobeNewswire

a month ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

a month ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

a month ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

a month ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

a month ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

USA TODAY

a month ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Simply Wall St.

a month ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"

CBS News Videos

a month ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Simply Wall St.

a month ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Short Report: Bears bite into Krispy Kreme after another weak earnings report

TipRanks

a month ago

Short Report: Bears bite into Krispy Kreme after another weak earnings report

John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage

GuruFocus.com

2 months ago

John Paulson's Strategic Move: Honeywell International Inc. Takes Center Stage

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

Motley Fool

2 months ago

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

GlobeNewswire

2 months ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

Insider Monkey

2 months ago

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential

Insider Monkey

2 months ago

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential

MT Newswires

2 months ago

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com

2 months ago

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Zacks

2 months ago

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MT Newswires

2 months ago

Madrigal Pharmaceuticals Q1 Loss Narrows

Associated Press Finance

2 months ago

Madrigal: Q1 Earnings Snapshot

Madrigal’s MASH drug sales again top Wall Street projections

BioPharma Dive

2 months ago

Madrigal’s MASH drug sales again top Wall Street projections

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire

2 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

GlobeNewswire

2 months ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks in the US Market

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

GlobeNewswire

2 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

GlobeNewswire

3 months ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Insider Monkey

3 months ago

Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks in the US Market

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

3 months ago

Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

GlobeNewswire

4 months ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

TipRanks

4 months ago

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

TipRanks

4 months ago

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

MT Newswires

4 months ago

B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236

MT Newswires

4 months ago

Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn

Simply Wall St.

4 months ago

We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn

High Growth Tech Stocks In US For February 2025

Simply Wall St.

4 months ago

High Growth Tech Stocks In US For February 2025

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com

4 months ago

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Benzinga

4 months ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

MT Newswires

4 months ago

Madrigal Pharmaceuticals Shares Jump After Q4 Beat, Release of New Data on Steatohepatitis Drug

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Zacks

4 months ago

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Motley Fool

4 months ago

Why Madrigal Pharmaceuticals Stock Is Soaring Today

MT Newswires

4 months ago

Madrigal Pharmaceuticals Says Steatohepatitis Drug Shows 'Marked Reductions' in Patients' Liver Stiffness

MT Newswires

4 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Wednesday

MT Newswires

4 months ago

Madrigal Pharmaceuticals' Q4 Net Loss Narrows, Revenue Tops Estimates

Associated Press Finance

4 months ago

Madrigal: Q4 Earnings Snapshot

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire

4 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire

4 months ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

GlobeNewswire

4 months ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

GlobeNewswire

5 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 01/28/2025

MT Newswires

5 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $531,020, According to a Recent SEC Filing

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

5 months ago

Exploring Three High Growth Tech Stocks in the United States

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

Motley Fool

5 months ago

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

Zacks

6 months ago

MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales

MT Newswires

6 months ago

Update: Madrigal Pharmaceuticals Shares Decline After Posting Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million

Why Madrigal Pharmaceuticals Stock Is Sinking Today

Motley Fool

6 months ago

Why Madrigal Pharmaceuticals Stock Is Sinking Today

MT Newswires

6 months ago

Madrigal Pharmaceuticals Reports Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

6 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks In The United States

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Simply Wall St.

6 months ago

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

TipRanks

7 months ago

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

MT Newswires

7 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

Motley Fool

7 months ago

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

7 months ago

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

Insider Monkey

7 months ago

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

The first MASH drug could open the door for others — including GLP-1s

Pharma Voice

7 months ago

The first MASH drug could open the door for others — including GLP-1s

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

GuruFocus.com

8 months ago

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Zacks

8 months ago

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

Motley Fool

8 months ago

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Zacks

8 months ago

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

3 High Growth Tech Stocks Leading The US Market

Simply Wall St.

8 months ago

3 High Growth Tech Stocks Leading The US Market

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

MT Newswires

8 months ago

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing

MT Newswires

8 months ago

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations

GuruFocus.com

8 months ago

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

TipRanks

8 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts

Simply Wall St.

8 months ago

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts

Madrigal Pharmaceuticals stock jumps on MASH drug hopes

Yahoo Finance Video

8 months ago

Madrigal Pharmaceuticals stock jumps on MASH drug hopes

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Investor's Business Daily

8 months ago

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

MT Newswires

8 months ago

UBS Adjusts Price Target on Madrigal Pharmaceuticals to $441 From $411, Maintains Buy Rating

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up

Zacks

8 months ago

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...

GuruFocus.com

8 months ago

Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...

MT Newswires

8 months ago

Sector Update: Health Care

MT Newswires

8 months ago

Madrigal Pharmaceuticals' Shares Rise After Reporting Narrower Q3 Loss

Associated Press Finance

8 months ago

Madrigal: Q3 Earnings Snapshot

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

GlobeNewswire

8 months ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

Clinical Trials Arena

8 months ago

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

Share on Social Networks: